The Study is Being Conducted to to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of Serplulimab Injection (HLX10) and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Conditions: Carcinoma, Hepatocellular Interventions: Drug: HLX53 (1000mg); Drug: HLX53 (2000mg); Drug: HLX10; Drug: HLX04; Other: Placebo Sponsors: Shanghai Henlius Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials